SCLnow -19 (Sclnow Biotechnology)

N/A

Report date: 2023/01/12 15:30:25

Base Information

Drug NameSCLnow -19 (Sclnow Biotechnology)

Drug Alias NamehUC-MSChUC-MSC - Sclnow BiotechnologyCord blood stem cell therapy - Sclnow BiotechnologyUmbilical cord-derived allogeneic mesenchymal stem cells therapy - Sclnow Biotechnology

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsFibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSclnow Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSclnow Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsFibrosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A